<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710827</url>
  </required_header>
  <id_info>
    <org_study_id>91579</org_study_id>
    <secondary_id>2008-002053-20</secondary_id>
    <secondary_id>310874</secondary_id>
    <nct_id>NCT00710827</nct_id>
  </id_info>
  <brief_title>Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks</brief_title>
  <official_title>A 54 Week Treatment, Randomized, Multi Center, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of NEBIDO 1000 mg (4 ml) in Elderly Men With Symptomatic Late Onset Hypogonadism (SLOH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Nebido compared to placebo in elderly men aged 50 and&#xD;
      over with symptomatic late onset hypogonadism&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explorative objectives: Change in grip strength (Subgroup only: optional for sites with&#xD;
      experienced in testing muscle function); Change in physical performance test i.e. lower limb&#xD;
      muscle strength (subgroup only; optional for sites experienced in testing muscle function).&#xD;
      Please note that the 2 explorative objectives mentioned above must be performed together. All&#xD;
      measured at baseline, week 30, week 54, no safety measure. Safety parameters Prostate safety:&#xD;
      digital rectal examination (DRE) Measured at screening, week 30+ 54, safety measure.&#xD;
      International prostate symptom score (IPSS): International prostate symptom score (IPSS)&#xD;
      Measured at screening, week 18, 30, 42, 54, safety measure. Laboratory tests for lipids&#xD;
      (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides) and liver function&#xD;
      tests (aspartate aminotransferase (AST) and alanine transaminase (ALT)) Measured at&#xD;
      screening, week 6, 18, 30, 42, 54, safety measure. Standard laboratory tests for androgen&#xD;
      treatment: prostate specific antigen (PSA); hemoglobin; hematocritMeasured at screening, week&#xD;
      6, 18, 30, 42, 54, safety measureAdverse eventsMeasured at screening, baseline, week 6, 18,&#xD;
      30, 42, 54Vital signsMeasured at screening, week 18, 30, 42, 54, safety measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">October 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the change from baseline in lean body mass after 54 weeks of treatment with NEBIDO compared to placebo</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total body mass</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fat mass</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone mineral density</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging Male Symptoms (AMS) rating scale</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function- erectile function domain (IIEF-EF)</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum levels of testosterone (central laboratory)</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>Baseline, week 30, week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEBIDO</intervention_name>
    <description>Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged 50 years and older&#xD;
&#xD;
          -  Symptomatic hypogonadism as defined by a) and b):&#xD;
&#xD;
          -  a) Total testosterone below 12nmol/l&#xD;
&#xD;
          -  b) Aging males symptom score above 36&#xD;
&#xD;
          -  Willing to avoid significant change in the pattern of physical exercise and lifestyle&#xD;
             for the duration of the study&#xD;
&#xD;
          -  Willing to voluntarily sign a statement of informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of androgen therapy or anabolic steroids&#xD;
&#xD;
          -  Suspicion or known history of liver tumors, prostate or breast cancer&#xD;
&#xD;
          -  Hypersensitivity to the active substances or any of the excipients of NEBIDO e.g.&#xD;
             Benzyl benzoate and castor oil. Hypercalcemia accompanying malignant tumors&#xD;
&#xD;
          -  Blood coagulation irregularities presenting an increased risk of bleeding after&#xD;
             intramuscular injections sleep apnea&#xD;
&#xD;
          -  Polycythemia&#xD;
&#xD;
          -  Hematocrit level &gt;50% at entry to the study (i.e. screening visit/visit 1)&#xD;
&#xD;
          -  Patients using 5-a-reductase inhibitors such as finasteride or dutasteride should be&#xD;
             excluded from the study.&#xD;
&#xD;
          -  Prolactin level &gt;25ng/ml&#xD;
&#xD;
          -  Organic hypothalamic-pituitary pathology&#xD;
&#xD;
          -  Prostate specific antigen (PSA) level ≥ 4ng/ml&#xD;
&#xD;
          -  Severe symptomatic benign prostatic hyperplasia (IPSS sum score ≥ 20)&#xD;
&#xD;
          -  Epilepsy not adequately controlled by treatment&#xD;
&#xD;
          -  Migraine not adequately controlled by treatment&#xD;
&#xD;
          -  Patients requiring or undergoing fertility treatment&#xD;
&#xD;
          -  Any clinically significant chronic disease that might, in the opinion of the&#xD;
             investigator, compromise patient's safety interfere with the evaluations, or preclude&#xD;
             completion of the trial (e.g. hemochromatosis, chronic lung disease, chronic&#xD;
             malabsorption disease)&#xD;
&#xD;
          -  Known history of alcohol or drug abuse&#xD;
&#xD;
          -  Medical, psychiatric or other conditions that compromise the patient's ability to&#xD;
             understand the patient information, to give informed consent, to comply with the trial&#xD;
             protocol, or to complete the study.&#xD;
&#xD;
          -  Hypertension which is not adequately controlled on therapy&#xD;
&#xD;
          -  Severe cardiac, hepatic or renal insufficiency&#xD;
&#xD;
          -  Coronary heart disease not stabilized by therapy as assessed by the investigator&#xD;
&#xD;
          -  Metal implants in the body (metal implants in the head will not exclude patients from&#xD;
             participation)&#xD;
&#xD;
          -  Concomitant participation in another clinical trial within 1 month of entry into this&#xD;
             study (i.e. randomized and has taken study medication).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>91-425</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01-432</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>123367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lichfield</city>
        <state>Staffordshire</state>
        <zip>WS14 9JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <state>Stratchclyde</state>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <zip>CF14 5GJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chorley</city>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW9 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>November 22, 2012</last_update_submitted>
  <last_update_submitted_qc>November 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer Healthcare AG</organization>
  </responsible_party>
  <keyword>NEBIDO,</keyword>
  <keyword>Hypogonadism,</keyword>
  <keyword>Symptomatic late onset,</keyword>
  <keyword>Testosterone deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone undecanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

